Thorax:低剂量CT筛查对肺癌筛查试验中高风险参与者戒烟的影响

2017-07-18 xiangting MedSci原创

高风险者的CT肺癌筛查对戒烟有教育作用,特别是那些收到阳性扫描结果的患者。

这项研究探讨了在英国肺癌筛查(UKLS)低剂量CT筛查试点试验中高风险的当前吸烟者中戒烟的影响。

完成基线调查问卷的50-75岁高风险个体被随机分为CT筛查(干预组)或常规治疗(无筛查对照组)。在基线使用自我报告确定吸烟习惯。询问吸烟者是否在加入UKLS后的短期随访期间(基线扫描结果或对照任务后2周)以及长期随访期间(入组后2年)戒烟。进行意向治疗(ITT)回归分析,根据基线肺癌呼吸困难,试验地点和社会人口学变量进行调整。

共有4055例患者随机接受CT筛查或对照,1546例为基线吸烟者(787例对照,759例干预)。戒烟率分别为2周时5%(对照组n = 36/786)vs.10%(干预组n = 75/758),和随访2年时10%(对照组n = 79/775)vs.15%(干预n = 115/749)。ITT分析表明,筛查组戒烟的几率在短期内显著升高(调整OR(aOR)2.38,95%CI 1.56-3.64,p <0.001)和长期(aOR 1.60,95%CI 1.17-2.18 ,p = 0.003)。与对照组(aOR 2.29,95%CI 1.62-3.22,p = 0.007)和收到阴性结果的患者(aOR 2.43,95%CI 1.54-3.84,p <0.001)相比,需要额外临床检查的干预组患者长期更有可能戒烟。

高风险者的CT肺癌筛查对戒烟有教育作用,特别是那些收到阳性扫描结果的患者。需要进一步的行为研究来评估整合戒烟干预与分层肺癌筛查的最佳策略。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-07-29 执迷不悔

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1803791, encodeId=bff11803e91f4, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Fri Apr 13 09:47:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862024, encodeId=9dfe1862024b0, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Sep 28 02:47:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768896, encodeId=ab221e688961e, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Apr 16 18:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227675, encodeId=2d0c22e6756d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/y6Sk2KiaDibWSs0icexcRzKWXKao9dILdyaB6olvWApA1uiaapa4T9XMiaU7hTZA04uj2iavabfdCT5iaO6AYue5qSJ7MzXaAVSqh6j/0, createdBy=08e01983553, createdName=执迷不悔, createdTime=Sat Jul 29 13:39:01 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423964, encodeId=269a1423964df, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480453, encodeId=0a711480453c9, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Jul 20 02:47:00 CST 2017, time=2017-07-20, status=1, ipAttribution=)]

相关资讯

病例:一个患者,三处肺癌,基因突变各有不同

一名既往吸烟史亚裔女患,双肺先后发现3处肺腺癌病灶,术后发现其肿瘤特征及基因状态存在异质性,应用二代测序技术首次发现NF1与EGFR基因的同时突变,提示适当时可应用测序技术更好地揭示肿瘤全貌,方可有的放矢。62岁既往吸烟史、甲状腺癌病史的亚裔女性患者,于日本旭川医科大学诊断为肺占位,术前CT显示患者双肺总计3枚结节,一枚为磨玻璃样结节,另两枚为实性结节(图1)。患者接受了左肺上叶切除及纵膈淋巴结清

Circulation:电子香烟依旧难逃心血管疾病风险

越来越多的数据显示,电子香烟可能不像我们期待的那样健康,尤其它的使用很可能会增加心血管疾病的风险。初步的研究结果已经认为,电子香烟的使用可能会引发心血管系统的改变,甚至于心血管疾病风险的增加相关。

这种肺癌多发于被动吸烟女性,呼吸科医生提倡健康烹调方式

7月9日,1983年版《神雕侠侣》中饰演黄蓉出名的香港演员欧阳佩珊因肺腺癌去世,享年63岁。回顾往昔,喜剧表演艺术家赵丽蓉老师(享年72岁)和“帽子歌后”凤飞飞(享年60岁)均因肺腺癌猝逝。2015年统计数据表明,中国女性每十万人中就有2-2.4万人患肺癌,其中,肺腺癌发生比例居首,占一半以上。什么是肺腺癌?肺腺癌是肺癌的一种,属于非小细胞癌,较容易发生于被动吸烟的女性。肺腺癌大多起源于较小的支气

Sci Rep:中药复方——养阴解毒汤能阻断肺癌细胞周期及诱导肺癌细胞衰老

肺癌是最常见的恶性肿瘤,同时也是世界上癌症相关死亡的主要原因。在中国,肺癌占所有癌症新发病例的六分之一,且死亡率高达6.102/1000,占所有肿瘤相关死亡的1/5。尽管有越来越多的新的治疗方法不断出现,但5年生存率依然不到20%。肺癌患者较差的预后,强调需要发现高效新型药物。中药已经被用来治疗人类疾病几百年了。现代研究证明,中药联合化疗在肿瘤的治疗中起着重要的作用,包括增强化疗的效果,减轻患者痛

J Thorac Oncol:一个患者,三处肺癌,基因突变各有不同

一名既往吸烟史亚裔女患,双肺先后发现3处肺腺癌病灶,术后发现其肿瘤特征及基因状态存在异质性,应用二代测序技术首次发现NF1与EGFR基因的同时突变,提示适当时可应用测序技术更好地揭示肿瘤全貌,方可有的放矢。

JAMA Oncol:临床免疫特征评估用于非小细胞肺癌患者的预后评估

临床免疫特征评估是估计非鳞状非小细胞肺癌患者总生存率的一种极具前景的方法,甚至可用于疾病早期,该前瞻性的非鳞状非小细胞肺癌生物标志物研究将加速临床个体化治疗的发展。